Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemafibrate vs omega-3 fatty acid ethyl esters in hypertriglyceridemia with NAFLD
jRCTs041200011Completed
- Sponsor
- Soiken Holdings
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pemafibrate in hypertriglyceridemia, metabolic dysfunction-associated steatotic liver disease (MASLD) and steatosis (2 arms), sponsored by Soiken Holdings. Primary endpoint: Change in ALT from baseline to week 24. Started Jun 2020; status: completed.
02
Drugs
pemafibrate
03
Conditions
hypertriglyceridemiametabolic dysfunction-associated steatotic liver disease (MASLD)steatosis
Beyond the preview
Go deeper on jRCTs041200011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200011.